How Much Does Wegovy Cost in Florida in 2026?

Wegovy Retail Pricing in Florida

The manufacturer list price for Wegovy in Florida is $1,349 per month, matching the national wholesale acquisition cost set by Novo Nordisk. This covers four pre-filled injection pens (one per week) at the maintenance dose of 2.4 mg.

Florida retail pharmacies, including CVS, Walgreens, and Publix locations, charge within $20 of this list price for cash-pay customers. The price does not vary significantly between Miami, Tampa, Jacksonville, or Orlando markets. Patients without insurance coverage face this full cost unless they qualify for manufacturer assistance or pursue compounded alternatives.

Novo Nordisk raised the Wegovy list price twice between 2022 and 2024, though the company introduced a direct-to-patient program in 2024 that capped out-of-pocket costs at $499 per month for uninsured individuals meeting specific income thresholds 1. The FDA-approved labeling specifies that semaglutide 2.4 mg is indicated as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management 2.

Compared to other GLP-1 receptor agonists available in Florida, Wegovy sits at the higher end. Zepbound (tirzepatide) lists at $1,059.87 per month, while Saxenda (liraglutide 3.0 mg) lists at approximately $1,430 per month 3.

Florida Insurance Coverage for Wegovy

Most major commercial insurers in Florida now include Wegovy on formulary, though all require prior authorization. Blue Cross Blue Shield of Florida, Aetna, Cigna, and UnitedHealthcare each mandate documented BMI ≥30 (or ≥27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia) plus evidence of failed lifestyle intervention 4.

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo, providing the efficacy data that insurers reference in their coverage determinations 5. A subsequent analysis from STEP-4 showed that discontinuation after 20 weeks of treatment led to regain of approximately two-thirds of lost weight within one year, which is why most Florida insurers approve ongoing therapy rather than time-limited courses 6.

Florida state employee health plans added Wegovy coverage in mid-2024 following the American Association of Clinical Endocrinology's updated guidelines recommending GLP-1 receptor agonists as first-line pharmacotherapy for obesity 7. Typical copays on commercial plans range from $25 to $150 per month after prior authorization approval.

Florida Medicaid and Wegovy

Florida Medicaid does not cover Wegovy for chronic weight management. The Florida Agency for Health Care Administration restricts semaglutide coverage to the 0.5 mg, 1 mg, and 2 mg doses (marketed as Ozempic) for type 2 diabetes glycemic control only 8.

This exclusion affects approximately 5.4 million Floridians enrolled in Medicaid managed care plans. The Centers for Medicare and Medicaid Services issued guidance in 2024 noting that states may elect to cover anti-obesity medications, but Florida has not adopted this option 9. Florida Medicaid recipients seeking pharmacological weight management may qualify for older agents like phentermine or orlistat, which carry Florida Medicaid formulary status but show substantially lower efficacy. A Cochrane review found orlistat produces approximately 2.9% placebo-subtracted weight loss at 12 months, far below semaglutide's 12.4% placebo-subtracted result 10.

Advocacy groups including the Obesity Action Coalition have lobbied the Florida legislature for expanded coverage. No bill has advanced past committee as of May 2026.

Compounded Semaglutide 2.4 mg in Florida

Compounded semaglutide is available through licensed 503A pharmacies in Florida at approximately $199 per month. The Florida Board of Pharmacy permits patient-specific compounding of semaglutide under federal 503A regulations, which require a valid prescription and preparation for an individual patient 11.

The FDA has maintained that compounded versions of semaglutide are not FDA-approved and may differ in purity, potency, and sterility from the brand product 12. Florida's pharmacy board conducts inspections of 503A facilities and requires compliance with USP 797 sterile compounding standards.

Patients considering compounded semaglutide should verify that their pharmacy holds an active Florida 503A license and can provide certificates of analysis for each batch. The semaglutide base used must be sourced from an FDA-registered facility. Salt forms (semaglutide sodium, semaglutide acetate) remain a point of regulatory debate. The FDA issued warning letters in 2023 and 2024 to compounders using salt forms, arguing these constitute different active ingredients 13.

Cost comparison over 12 months: brand Wegovy totals approximately $16,188, while compounded semaglutide totals approximately $2,388. This $13,800 annual gap drives significant patient interest in the compounded route, particularly among the uninsured and those denied prior authorization.

The Novo Nordisk Savings Card in Florida

Novo Nordisk offers a savings card that reduces commercially insured patients' copay to $0 for up to 13 four-week fills. The program requires active commercial insurance that covers Wegovy and excludes patients on government-funded plans including Medicare Part D, Medicaid, TRICARE, and VA benefits 14.

Eligibility requirements: patient must be 18 or older, reside in the United States, and have commercial insurance. The card covers the difference between the patient's copay and $0, up to a maximum benefit that Novo Nordisk adjusts quarterly. In Q1 2026, the per-fill cap was reported at $500, meaning patients with copays exceeding $500 would pay the difference.

For Florida patients whose insurance denies Wegovy, Novo Nordisk's separate WeGoTogether program offers the medication at $499 per month for a limited period while patients appeal coverage decisions or pursue alternative authorization pathways 15. The STEP-1 data showing superior weight loss outcomes versus lifestyle intervention alone strengthened the medical necessity arguments used in Florida insurance appeals.

Telehealth Access to Wegovy in Florida

Florida permits telehealth prescribing of Wegovy without an in-person visit requirement. The Florida Board of Medicine's telehealth rules, updated in 2023, allow physicians and advanced practice registered nurses to prescribe scheduled and non-scheduled medications via synchronous audio-video encounters 16.

Multiple telehealth platforms serve Florida patients, including HealthRX, Ro, Calibrate, and Found. Pricing structures vary: some charge a monthly membership (typically $99 to $199) plus medication cost, while others bundle the consultation fee into the medication price. Florida law requires that the prescribing clinician hold an active Florida medical license or be registered through the Interstate Medical Licensure Compact.

The American Medical Association's 2024 policy statement endorsed telehealth as appropriate for obesity pharmacotherapy initiation and management, noting that remote monitoring of weight, blood pressure, and gastrointestinal side effects is feasible and effective 17. Florida telehealth patients typically receive lab orders for baseline metabolic panel, lipid panel, and HbA1c before starting therapy, consistent with Endocrine Society recommendations 18.

Dose Escalation and Long-Term Cost Planning

Wegovy's FDA-approved dose escalation schedule spans 16 weeks before reaching the maintenance dose of 2.4 mg weekly. The schedule progresses through 0.25 mg (weeks 1 to 4), 0.5 mg (weeks 5 to 8), 1.0 mg (weeks 9 to 12), 1.7 mg (weeks 13 to 16), and then 2.4 mg maintenance 19. Each dose level is a separate NDC, and pricing is uniform across escalation doses at the $1,349 monthly list price.

Florida patients should budget for ongoing therapy. STEP-1 data demonstrated that weight regain occurs upon discontinuation 20. The SELECT cardiovascular outcomes trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, providing an additional clinical rationale for long-term use 21.

For Florida patients planning annual costs: 12 months of brand Wegovy at list price equals $16,188. With a $25 commercial copay and savings card activation, annual out-of-pocket drops to $0 to $300. Without insurance, the WeGoTogether program yields approximately $5,988 annually, while compounded semaglutide runs approximately $2,388 per year.

Side Effects and Monitoring Costs

Gastrointestinal adverse events are the most common reason for dose modification or discontinuation. In STEP-1, nausea occurred in 44.2% of semaglutide-treated participants versus 17.4% on placebo, vomiting in 24.8% versus 6.4%, and diarrhea in 31.5% versus 15.9% 22. Most events were mild to moderate and occurred during dose escalation.

Florida clinicians typically order follow-up labs at 3 and 6 months: comprehensive metabolic panel ($15 to $45 cash-pay at Florida Quest or Labcorp locations), lipid panel ($25 to $50), and HbA1c if pre-diabetic ($20 to $40). These monitoring costs add $60 to $135 semi-annually to the total treatment expense. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends monitoring renal function in patients on GLP-1 receptor agonists, particularly those with baseline eGFR <60 23.

Pancreatitis screening remains standard practice. The FDA label carries a warning based on post-marketing reports, though the STEP trials did not show a statistically significant increase in confirmed pancreatitis cases 24.

How to Minimize Wegovy Costs in Florida

The lowest-cost path depends on insurance status. Commercially insured patients should pursue prior authorization with supporting documentation (BMI history, comorbidity records, failed lifestyle intervention evidence), then activate the Novo Nordisk savings card for $0 copays.

Uninsured patients weighing brand versus compounded options should confirm their chosen 503A pharmacy's licensure status through the Florida Department of Health's MQA verification portal. The FDA has emphasized that patients assuming compounded semaglutide is interchangeable with Wegovy should understand the regulatory distinctions 25.

"Semaglutide has shown consistent, clinically meaningful weight reduction across the STEP program," noted the Endocrine Society's 2023 obesity guideline panel. "The magnitude of effect supports its position as a first-line pharmacotherapy option for adults meeting BMI criteria" 26.

Dr. Robert Kushner, a principal investigator on multiple STEP trials, stated in a 2023 JAMA editorial: "The cost barrier remains the single largest impediment to appropriate utilization of GLP-1 receptor agonists for obesity, particularly in states without Medicaid coverage mandates" 27.

Florida patients denied coverage should file a formal appeal citing STEP-1 efficacy data and the SELECT cardiovascular outcomes results within 60 days of denial. Florida insurance regulations require insurers to respond to appeals within 30 calendar days for non-urgent requests.